{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000068","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.911171+00:00","generated_at":"2026-06-08T06:50:21.895202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"vTv Therapeutics Q3 net loss widens to $6.7M; cash drops to $8.2M","bullets":["Net loss of $6.7M ($0.08 per share) vs $4.3M ($0.05) in Q3 2022.","Cash and equivalents fell to $8.2M from $12.1M at Dec. 31, 2022.","R&D expenses were $2.8M, down from $3.1M YoY on lower cadisegliatin costs.","Appointed Dr. Thomas Strack as Chief Medical Officer on November 2, 2023.","Received $4.4M from Reneo for repurchase of Reneo common stock on Nov 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000068","json":"https://secwatch.observer/filing/0001641489-23-000068.json","markdown":"https://secwatch.observer/filing/0001641489-23-000068.md","text":"https://secwatch.observer/filing/0001641489-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/0001641489-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/vtvt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:50:21.895202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6e0fc94aaf676c3d47c6e218fe4acd40e9c0add","claim":"vTv Therapeutics Inc. reported third quarter ended September 30, 2023 results: revenue $ —, net income $6.7 million, EPS $0.08 per basic share.","evidence_excerpt":"Net loss attributable to vTv shareholders for the three months ended September 30, 2023, was $6.7 million or $0.08 per basic share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000068/0001641489-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$ —"},{"label":"Net income","value":"$6.7 million"},{"label":"EPS","value":"$0.08 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}